Inventor · disambiguated record
Zhanling Cheng
Also filed as: CHENG ZHANLING
10 granted patents·19 pending applications·17 citations·filing 2015–2023
82Inventor score
Files withHOFFMANN LA ROCHE18JANSSEN SCIENCES IRELAND UNLIMITED CO8JANSSEN PHARMACEUTICA NV2Janssen Phrmaceutica NV1
Top patents by PatentIndex Score
29 records- 0191US9845322B2Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2016·Granted Dec 19, 2017·7 cites·46 claims
- 0281US11104674B2Tetrahydropyridopyrimidines for the treatment of HBV infectionHOFFMANN LA ROCHE·Filed 2018·Granted Aug 31, 2021·2 cites·33 claims
- 0380US10336751B2Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2018·Granted Jul 2, 2019·3 cites·12 claims
- 0480US10150740B26,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2018·Granted Dec 11, 2018·3 cites·15 claims
- 0576US10196391B2Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2017·Granted Feb 5, 2019·2 cites·12 claims
- 0662US2023257354A1Novel heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0761US2025011326A1Fused heterocyclic derivatives and their use in the treatment of hbv infectionJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2023·Application pending·0 cites
- 0861US2023141600A1Imidazopyrazine derivativesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 0960US2023141403A1Novel imidazopyrazine derivativesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1058US2022396565A1Novel heterocyclic compoundsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1157US2024279227A1Fused heterocyclic derivativesJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2022·Application pending·0 cites
- 1257US2024287070A1Fused heterocyclic derivativesJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2022·Application pending·0 cites
- 1354US2023012368A1Novel imidazopyrazine derivativesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1453US11225482B2Dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2018·Granted Jan 18, 2022·0 cites·17 claims
- 1553US11053235B2Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseasesJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2019·Granted Jul 6, 2021·0 cites·17 claims
- 1653US2023022724A1Novel imidazopyrazine derivativesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1753US2023017532A1Novel imidazopyrazine derivativesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1853US2023011869A1Novel imidazopyrazine derivativesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1952US2022348571A1Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseasesJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2019·Application pending·0 cites
- 2050US2023002408A1Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infectionsJANSSEN PHARMACEUTICA NV·Filed 2020·Application pending·0 cites
- 2148US2022267313A1Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseasesJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2020·Application pending·0 cites
- 2247US10968218B2Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2017·Granted Apr 6, 2021·0 cites·14 claims
- 2346US2023165865A1Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infectionsJANSSEN PHARMACEUTICA NV·Filed 2019·Application pending·0 cites
- 2446US2022281865A1Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseasesJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2020·Application pending·0 cites
- 2544US11124495B2Tetrahydroisoquinolines and terahydronaphthyridines for the treatment of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2017·Granted Sep 21, 2021·0 cites·19 claims
- 2644US2022048919A1Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infectionsJanssen Phrmaceutica NV·Filed 2019·Application pending·0 cites
- 2743US10968217B2Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infectionHOFFMANN LA ROCHE·Filed 2017·Granted Apr 6, 2021·0 cites·14 claims
- 2840US2023083012A1Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseasesJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2020·Application pending·0 cites
- 2934US2015266878A1Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancerHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zhanling Cheng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →